Zentalis Pharmaceuticals
ZNTL
95 hedge funds and large institutions have $1.58B invested in Zentalis Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 38 increasing their positions, 26 reducing their positions, and 25 closing their positions.
46% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 26
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.33% less ownership
Funds ownership: 91.85% → 88.52% (-3.3%)
11% less funds holding
Funds holding: 107 → 95 (-12)
19% less capital invested
Capital invested by funds: $1.94B → $1.58B (-$361M)
48% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$26.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$24.9M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$11.7M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$9.69M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$5.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$54.5M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$26.3M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$20.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$19.3M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$8.41M |
ZNTL Hedge Fund Activity: Q1 2021 in Review
95 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q1 2021, worth a combined $1.58B — down 19% from $1.94B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ZNTL and 13 opened new positions — a net loss of 12 holders — while 26 trimmed existing stakes and 38 added.
The largest buyer was Federated Hermes, adding an estimated $26.9M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $54.5M sold.
- 95 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q1 2021, down from 107 in Q4 2020.
- Funds reported $1.58B of Zentalis Pharmaceuticals stock for Q1 2021, down 19% quarter-over-quarter.
- 13 funds opened new Zentalis Pharmaceuticals positions in Q1 2021 and 25 closed out, a net change of -12 holders.
- The largest Zentalis Pharmaceuticals buyer in Q1 2021 was Federated Hermes, an estimated $26.9M added.
- The largest Zentalis Pharmaceuticals seller in Q1 2021 was Perceptive Advisors, an estimated $54.5M sold.
Based on aggregated 13F filings for Q1 2021.